argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 okt 2016 - 07:00
Statutaire naam
argenx SE
Titel
Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody(TM)
Bericht
argenx's specific drug candidates include ARGX-113 for myasthenia gravis, ARGX-110 for cancer immunotherapy, and ARGX-111 for c-MET
London UK / Breda, the Netherlands / Ghent, Belgium - Based on its recent analysis of the therapeutic antibody engineering market, Frost & Sullivan recognises argenx N.V. with the 2016 European Frost & Sullivan Award for Technology Innovation. argenx's SIMPLE Antibody(TM) discovery platform is a huge improvement on conventional antibody discovery platforms because it yields an unprecedented epitope coverage, allowing to interact with the disease biology in a much more precise manner. The application diversity of the platform enables it to generate a wide array of antibodies for different types of cancer and autoimmune disorders.
Gerelateerde downloads
Datum laatste update: 21 december 2025